Terry L. Poling

Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

N. Kanesa-thasan, M. Hohenboken, P. Jaehnig, 2015, The Journal of infectious diseases.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

A. Falsey, G. Gorse, J. Fling, 2013, Vaccine.

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.

E. Kerwin, H. Watz, F. Maltais, 2022, The Lancet. Respiratory medicine.

Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study

D. Vaughn, J. Langley, Ping Li, 2011, The Journal of infectious diseases.

Risk of COVID-19 after natural infection or vaccination

Nicole L. Nollen, Eric A. Meyerowitz, Waseem M. Chughtai, 2023, EBioMedicine.